Literature DB >> 26511018

Effect of radioactive iodine therapy on carotid intima media thickness in patients with hyperthyroidism.

Bekir Şanal1, İlknur Işık2, Mehmet Korkmaz3, Cüneyt Kucur4, Fatma Can3, Türkan Paşalı Kilit5, Cüneyt Kahraman5, Emre Kaçar6, Ahmet Koçak7.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the carotid intima media thickness (IMT) in patients with thyrotoxicosis who received radioactive iodine (RAI) treatment.
METHODS: This study was planned to be conducted with two different groups of people. There were 87 patients in the patient group and 98 controls. Participants were evaluated for atherosclerosis risk factors. Mean carotid IMT was measured from three consecutive traces at the common carotid artery bifurcation.
RESULTS: The mean carotid IMT was 0.81 ± 0.20 in patient group and this was higher than the controls (0.68 ± 0.19) (p < 0.01). IM thickening was positively correlated with the applied RAI dose levels in the treatment group (p = 0.029). In patients with only HT, the data of the two groups showed a significant difference, with the average IMT being higher in the patient group than that of the control group (p: 0.011).
CONCLUSION: RAI used in the treatment of thyrotoxicosis increases the IMT of carotid artery independent of age and sex. This treatment yields better results with higher doses, and this effect is more marked in patients with HT. Hence, we believe that it is necessary to calculate the dose properly for hyperthyroid cases in which treatment with RAI is planned. In particular, the patients with HT need to be treated with the minimum possible dose. Further, carotid arteries should be evaluated with US following RAI treatment.

Entities:  

Keywords:  Hyperthyroidism; Intima media thickness (IMT); Radioactive iodine therapy (RAI)

Mesh:

Substances:

Year:  2015        PMID: 26511018     DOI: 10.1007/s12149-015-1033-z

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  2 in total

1.  Risk Factors for Cardiovascular Disease Among Thyroid Cancer Survivors: Findings From the Utah Cancer Survivors Study.

Authors:  Jihye Park; Brenna E Blackburn; Patricia A Ganz; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Michael Newman; Alison Fraser; Ken Smith; Kim Herget; Anne C Kirchhoff; Dev Abraham; Jaewhan Kim; Marcus Monroe; Mia Hashibe
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

2.  Long-term cardiovascular and cerebrovascular morbidity in Israeli thyroid cancer survivors.

Authors:  Elena Izkhakov; Joseph Meyerovitch; Micha Barchana; Yacov Shacham; Naftali Stern; Lital Keinan-Boker
Journal:  Endocr Connect       Date:  2019-04       Impact factor: 3.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.